Download PDF
Exp Clin Endocrinol Diabetes 2008; 116: S40-S45
DOI: 10.1055/s-2008-1081496
Review

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Sweet Heart – Contributions of Metabolism in the Development of Heart Failure in Diabetes Mellitus

B. Stratmann 1 , D. Tschoepe 1
  • 1Heart and Diabetes Center NRW, Ruhr-University Bochum, Oeynhausen, Germany
Further Information

Publication History

received 10.03.2008

accepted 02.05.2008

Publication Date:
05 September 2008 (online)

Also available at
    Permissions and Reprints

Abstract

With the rapidly increasing prevalence of type 2 diabetes mellitus the risk for cardiovascular events is increasing. Almost 2 of 3 patients who present with symptomatic CHD have abnormal glucose homeostasis. Patients with diabetes mellitus and cardiovascular disease have an unfavourable prognosis. The most important result of diabetes metabolism is the switch from carbohydrates and fatty acids as a source of energy to an excessive use of fatty acids. The adverse influence of diabetes mellitus extends to all components of the cardiovascular system, including microvasculature, the epicardial coronary arteries, the large conduit arteries and the heart, as well as the kidneys. Focus of this review is the myocardial metabolism in heart failure and diabetes mellitus.

Key words

diabetic cardiomyopathy - lipotoxicity - cardiac metabolism

References

  • 1 An D, Rodrigues B. Role of changes in cardiac metabolism in development of diabetic cardiomyopathy.  Am J Physiol Heart Circ Physiol. 2006;  291 H1489-H1506
    CrossrefPubMedGoogle Scholar
  • 2 Atkinson LL, Fischer MA, Lopaschuk GD. Leptin activates cardiac fatty acid oxidation independent of changes in the AMP-activated protein kinase-acetyl-CoA carboxylase-malonyl-CoA axis.  J Biol Chem. 2002;  277 29424-29430
    CrossrefPubMedGoogle Scholar
  • 3 Bell DS. Heart failure: the frequent, forgotten, and often fatal complication of diabetes.  Diabetes Care. 2003;  26 2433-2441
    CrossrefPubMedGoogle Scholar
  • 4 Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview.  Lancet. 2000;  355 773-778
    CrossrefPubMedGoogle Scholar
  • 5 Carroll R, Carley AN, Dyck JR, Severson DL. Metabolic effects of insulin on cardiomyocytes from control and diabetic db/db mouse hearts.  Am J Physiol Endocrinol Metab. 2005;  288 E900-E906
    PubMedGoogle Scholar
  • 6 Chiu HC, Kovacs A, Blanton RM, Han X, Courtois M, Weinheimer CJ, Yamada KA, Brunet S, Xu H, Nerbonne JM, Welch MJ, Fettig NM, Sharp TL, Sambandam N, Olson KM, Ory DS, Schaffer JE. Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy.  Circ Res. 2005;  96 225-233
    CrossrefPubMedGoogle Scholar
  • 7 Chiu HC, Kovacs A, Ford DA, Hsu FF, Garcia R, Herrero P, Saffitz JE, Schaffer JE. A novel mouse model of lipotoxic cardiomyopathy.  J Clin Invest. 2001;  107 813-822
    CrossrefPubMedGoogle Scholar
  • 8 Cohen P. The Croonian Lecture 1998. Identification of a protein kinase cascade of major importance in insulin signal transduction.  Philos Trans R Soc Lond B Biol Sci. 1999;  354 485-495
    PubMedGoogle Scholar
  • 9 Conway MA, Allis J, Ouwerkerk R, Niioka T, Rajagopalan B, Radda GK. Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31P magnetic resonance spectroscopy.  Lancet. 1991;  338 973-976
    CrossrefPubMedGoogle Scholar
  • 10 Coort SL, Hasselbaink DM, Koonen DP, Willems J, Coumans WA, Chabowski A, Vusse GJ van der, Bonen A, Glatz JF, Luiken JJ. Enhanced sarcolemmal FAT/CD36 content and triacylglycerol storage in cardiac myocytes from obese zucker rats.  Diabetes. 2004;  53 1655-1663
    CrossrefPubMedGoogle Scholar
  • 11 Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B.  Nature. 1995;  378 785-789
    CrossrefPubMedGoogle Scholar
  • 12 Davila-Roman VG, Vedala G, Herrero P, de las Fuentes L, Rogers JG, Kelly DP, Gropler RJ. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy.  J Am Coll Cardiol. 2002;  40 271-277
    CrossrefPubMedGoogle Scholar
  • 13 Finck BN, Han X, Courtois M, Aimond F, Nerbonne JM, Kovacs A, Gross RW, Kelly DP. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content.  Proc Natl Acad Sci USA. 2003;  100 1226-1231
    CrossrefPubMedGoogle Scholar
  • 14 Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, Lopaschuk GD, Kelly DP. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus.  J Clin Invest. 2002;  109 121-130
    PubMedGoogle Scholar
  • 15 Fulton D, Gratton JP, MacCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, Sessa WC. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt.  Nature. 1999;  399 597-601
    CrossrefPubMedGoogle Scholar
  • 16 Giles TD, Sander GE. Diabetes mellitus and heart failure: basic mechanisms, clinical features, and therapeutic considerations.  Cardiol Clin. 2004;  22 553-568
    CrossrefPubMedGoogle Scholar
  • 17 Golfman LS, Wilson CR, Sharma S, Burgmaier M, Young ME, Guthrie PH, Arsdall M Van, Adrogue JV, Brown KK, Taegtmeyer H. Activation of PPARgamma enhances myocardial glucose oxidation and improves contractile function in isolated working hearts of ZDF rats.  Am J Physiol Endocrinol Metab. 2005;  289 E328-E336
    CrossrefPubMedGoogle Scholar
  • 18 Guimbal C, Kilimann MW. A Na(+)-dependent creatine transporter in rabbit brain, muscle, heart, and kidney. cDNA cloning and functional expression.  J Biol Chem. 1993;  268 8418-8421
    PubMedGoogle Scholar
  • 19 Hardy CJ, Weiss RG, Bottomley PA, Gerstenblith G. Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy.  Am Heart J. 1991;  122 795-801
    CrossrefPubMedGoogle Scholar
  • 20 Held C, Gerstein HC, Yusuf S, Zhao F, Hilbrich L, Anderson C, Sleight P, Teo K. Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk.  Circulation. 2007;  115 1371-1375
    CrossrefPubMedGoogle Scholar
  • 21 Horio T, Suzuki M, Suzuki K, Takamisawa I, Hiuge A, Kamide K, Takiuchi S, Iwashima Y, Kihara S, Funahashi T, Yoshimasa Y, Kawano Y. Pioglitazone improves left ventricular diastolic function in patients with essential hypertension.  Am J Hypertens. 2005;  18 949-957
    CrossrefPubMedGoogle Scholar
  • 22 Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance.  Nature. 2006;  440 944-948
    CrossrefPubMedGoogle Scholar
  • 23 How OJ, Aasum E, Severson DL, Chan WY, Essop MF, Larsen TS. Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice.  Diabetes. 2006;  55 466-473
    CrossrefPubMedGoogle Scholar
  • 24 Hu P, Zhang D, Swenson L, Chakrabarti G, Abel ED, Litwin SE. Minimally invasive aortic banding in mice: effects of altered cardiomyocyte insulin signaling during pressure overload.  Am J Physiol Heart Circ Physiol. 2003;  285 H1261-H1269
    PubMedGoogle Scholar
  • 25 Ibrahimi A, Bonen A, Blinn WD, Hajri T, Li X, Zhong K, Cameron R, Abumrad NA. Muscle-specific overexpression of FAT/CD36 enhances fatty acid oxidation by contracting muscle, reduces plasma triglycerides and fatty acids, and increases plasma glucose and insulin.  J Biol Chem. 1999;  274 26761-26766
    CrossrefPubMedGoogle Scholar
  • 26 Ingwall JS. Is creatine kinase a target for AMP-activated protein kinase in the heart?.  J Mol Cell Cardiol. 2002;  34 1111-1120
    CrossrefPubMedGoogle Scholar
  • 27 Ingwall JS, Weiss RG. Is the failing heart energy starved? On using chemical energy to support cardiac function.  Circ Res. 2004;  95 135-145
    CrossrefPubMedGoogle Scholar
  • 28 Iozzo P, Chareonthaitawee P, Dutka D, Betteridge DJ, Ferrannini E, Camici PG. Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance.  Diabetes. 2002;  51 3020-3024
    CrossrefPubMedGoogle Scholar
  • 29 Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S, Selby JV. Glycemic control and heart failure among adult patients with diabetes.  Circulation. 2001;  103 2668-2673
    CrossrefPubMedGoogle Scholar
  • 30 Kalousova M, Skrha J, Zima T. Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus.  Physiol Res. 2002;  51 597-604
    PubMedGoogle Scholar
  • 31 Kannel WB. Incidence and epidemiology of heart failure.  Heart Fail Rev. 2000;  5 167-173
    CrossrefPubMedGoogle Scholar
  • 32 Kannel WB, MacGee DL. Diabetes and cardiovascular disease. The Framingham study.  Jama. 1979;  241 2035-2038
    CrossrefPubMedGoogle Scholar
  • 33 King KL, Okere IC, Sharma N, Dyck JR, Reszko AE, MacElfresh TA, Kerner J, Chandler MP, Lopaschuk GD, Stanley WC. Regulation of cardiac malonyl-CoA content and fatty acid oxidation during increased cardiac power.  Am J Physiol Heart Circ Physiol. 2005;  289 H1033-H1037
    CrossrefPubMedGoogle Scholar
  • 34 Koonen DP, Glatz JF, Bonen A, Luiken JJ. Long-chain fatty acid uptake and FAT/CD36 translocation in heart and skeletal muscle.  Biochim Biophys Acta. 2005;  1736 163-180
    PubMedGoogle Scholar
  • 35 Lamb HJ, Beyerbacht HP, Laarse A van der, Stoel BC, Doornbos J, Wall EE van der, Roos A de. Diastolic dysfunction in hypertensive heart disease is associated with altered myocardial metabolism.  Circulation. 1999;  99 2261-2267
    PubMedGoogle Scholar
  • 36 Lautamaki R, Airaksinen KE, Seppanen M, Toikka J, Harkonen R, Luotolahti M, Borra R, Sundell J, Knuuti J, Nuutila P. Insulin improves myocardial blood flow in patients with type 2 diabetes and coronary artery disease.  Diabetes. 2006;  55 511-516
    CrossrefPubMedGoogle Scholar
  • 37 Leone TC, Weinheimer CJ, Kelly DP. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders.  Proc Natl Acad Sci USA. 1999;  96 7473-7478
    CrossrefPubMedGoogle Scholar
  • 38 Luiken JJ, Coort SL, Koonen DP, Bonen A, Glatz JF. Signalling components involved in contraction-inducible substrate uptake into cardiac myocytes.  Proc Nutr Soc. 2004;  63 251-258
    PubMedGoogle Scholar
  • 39 Luiken JJ, Coort SL, Koonen DP, Horst DJ van der, Bonen A, Zorzano A, Glatz JF. Regulation of cardiac long-chain fatty acid and glucose uptake by translocation of substrate transporters.  Pflugers Arch. 2004;  448 1-15
    CrossrefPubMedGoogle Scholar
  • 40 Monti LD, Landoni C, Setola E, Galluccio E, Lucotti P, Sandoli EP, Origgi A, Lucignani G, Piatti P, Fazio F. Myocardial insulin resistance associated with chronic hypertriglyceridemia and increased FFA levels in Type 2 diabetic patients.  Am J Physiol Heart Circ Physiol. 2004;  287 H1225-H1231
    CrossrefPubMedGoogle Scholar
  • 41 Murray AJ, Anderson RE, Watson GC, Radda GK, Clarke K. Uncoupling proteins in human heart.  Lancet. 2004;  364 1786-1788
    CrossrefPubMedGoogle Scholar
  • 42 Neubauer S. The failing heart – an engine out of fuel.  N Engl J Med. 2007;  356 1140-1151
    CrossrefPubMedGoogle Scholar
  • 43 Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, Pabst T, Ertl G, Hahn D, Ingwall JS, Kochsiek K. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy.  Circulation. 1997;  96 2190-2196
    PubMedGoogle Scholar
  • 44 Neubauer S, Horn M, Pabst T, Godde M, Lubke D, Jilling B, Hahn D, Ertl G. Contributions of 31P-magnetic resonance spectroscopy to the understanding of dilated heart muscle disease.  Eur Heart J. 1995;  16 ((Suppl O)) 115-118
    PubMedGoogle Scholar
  • 45 Neubauer S, Krahe T, Schindler R, Horn M, Hillenbrand H, Entzeroth C, Mader H, Kromer EP, Riegger GA, Lackner K. et al . 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure.  Circulation. 1992;  86 1810-1818
    PubMedGoogle Scholar
  • 46 Norton GR, Candy G, Woodiwiss AJ. Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats.  Circulation. 1996;  93 1905-1912
    PubMedGoogle Scholar
  • 47 O’Keefe JH, Bell DS. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor.  Am J Cardiol. 2007;  100 899-904
    CrossrefPubMedGoogle Scholar
  • 48 Opie LH. Effect of fatty acids on contractility and rhythm of the heart.  Nature. 1970;  227 1055-1056
    CrossrefPubMedGoogle Scholar
  • 49 Osorio JC, Stanley WC, Linke A, Castellari M, Diep QN, Panchal AR, Hintze TH, Lopaschuk GD, Recchia FA. Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure.  Circulation. 2002;  106 606-612
    CrossrefPubMedGoogle Scholar
  • 50 Paz K, Hemi R, LeRoith D, Karasik A, Elhanany E, Kanety H, Zick Y. A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation.  J Biol Chem. 1997;  272 29911-29918
    CrossrefPubMedGoogle Scholar
  • 51 Peterson LR, Herrero P, Schechtman KB, Racette SB, Waggoner AD, Kisrieva-Ware Z, Dence C, Klein S, Marsala J, Meyer T, Gropler RJ. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women.  Circulation. 2004;  109 2191-2196
    CrossrefPubMedGoogle Scholar
  • 52 Razeghi P, Young ME, Alcorn JL, Moravec CS, Frazier OH, Taegtmeyer H. Metabolic gene expression in fetal and failing human heart.  Circulation. 2001;  104 2923-2931
    CrossrefPubMedGoogle Scholar
  • 53 Rosen P, Du X, Tschope D. Role of oxygen derived radicals for vascular dysfunction in the diabetic heart: prevention by alpha-tocopherol?.  Mol Cell Biochem. 1998;  188 103-111
    CrossrefPubMedGoogle Scholar
  • 54 Rui L, Aguirre V, Kim JK, Shulman GI, Lee A, Corbould A, Dunaif A, White MF. Insulin/IGF-1 and TNF-alpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways.  J Clin Invest. 2001;  107 181-189
    CrossrefPubMedGoogle Scholar
  • 55 Schupp M, Kintscher U, Fielitz J, Thomas J, Pregla R, Hetzer R, Unger T, Regitz-Zagrosek V. Cardiac PPARalpha expression in patients with dilated cardiomyopathy.  Eur J Heart Fail. 2006;  8 290-294
    CrossrefPubMedGoogle Scholar
  • 56 Shah A, Shannon RP. Insulin resistance in dilated cardiomyopathy.  Rev Cardiovasc Med. 2003;  4 ((Suppl 6)) S50-S57
    PubMedGoogle Scholar
  • 57 Sharma S, Adrogue JV, Golfman L, Uray I, Lemm J, Youker K, Noon GP, Frazier OH, Taegtmeyer H. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart.  Faseb J. 2004;  18 1692-1700
    CrossrefPubMedGoogle Scholar
  • 58 Simon HU, Haj-Yehia A, Levi-Schaffer F. Role of reactive oxygen species (ROS) in apoptosis induction.  Apoptosis. 2000;  5 415-418
    CrossrefPubMedGoogle Scholar
  • 59 Sliwa K, Damasceno A, Mayosi BM. Epidemiology and etiology of cardiomyopathy in Africa.  Circulation. 2005;  112 3577-3583
    CrossrefPubMedGoogle Scholar
  • 60 Stanley WC, Lopaschuk GD, MacCormack JG. Regulation of energy substrate metabolism in the diabetic heart.  Cardiovasc Res. 1997;  34 25-33
    CrossrefPubMedGoogle Scholar
  • 61 Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.  Bmj. 2000;  321 405-412
    CrossrefPubMedGoogle Scholar
  • 62 Susic D, Varagic J, Ahn J, Frohlich ED. Crosslink breakers: a new approach to cardiovascular therapy.  Curr Opin Cardiol. 2004;  19 336-340
    CrossrefPubMedGoogle Scholar
  • 63 Taegtmeyer H. Switching metabolic genes to build a better heart.  Circulation. 2002;  106 2043-2045
    CrossrefPubMedGoogle Scholar
  • 64 Taegtmeyer H, MacNulty P, Young ME. Adaptation and maladaptation of the heart in diabetes: Part I: general concepts.  Circulation. 2002;  105 1727-1733
    CrossrefPubMedGoogle Scholar
  • 65 Taegtmeyer H, Passmore JM. Defective energy metabolism of the heart in diabetes.  Lancet. 1985;  1 139-141
    PubMedGoogle Scholar
  • 66 Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action.  Nat Rev Mol Cell Biol. 2006;  7 85-96
    CrossrefPubMedGoogle Scholar
  • 67 Teusink B, Voshol PJ, Dahlmans VE, Rensen PC, Pijl H, Romijn JA, Havekes LM. Contribution of fatty acids released from lipolysis of plasma triglycerides to total plasma fatty acid flux and tissue-specific fatty acid uptake.  Diabetes. 2003;  52 614-620
    CrossrefPubMedGoogle Scholar
  • 68 Ungar I, Gilbert M, Siegel A, Blain JM, Bing RJ. Studies on myocardial metabolism. IV. Myocardial metabolism in diabetes.  Am J Med. 1955;  18 385-396
    CrossrefPubMedGoogle Scholar
  • 69 Heerebeek L van, Hamdani N, Handoko ML, Falcao-Pires I, Musters RJ, Kupreishvili K, Ijsselmuiden AJ, Schalkwijk CG, Bronzwaer JG, Diamant M, Borbely A, Velden J van der, Stienen GJ, Laarman GJ, Niessen HW, Paulus WJ. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension.  Circulation. 2008;  117 43-51
    CrossrefPubMedGoogle Scholar
  • 70 Vincent MA, Montagnani M, Quon MJ. Molecular and physiologic actions of insulin related to production of nitric oxide in vascular endothelium.  Curr Diab Rep. 2003;  3 279-288
    CrossrefPubMedGoogle Scholar
  • 71 Wyss M, Wallimann T. Creatine metabolism and the consequences of creatine depletion in muscle.  Mol Cell Biochem. 1994;  133–134 51-66
    PubMedGoogle Scholar
  • 72 Yagyu H, Chen G, Yokoyama M, Hirata K, Augustus A, Kako Y, Seo T, Hu Y, Lutz EP, Merkel M, Bensadoun A, Homma S, Goldberg IJ. Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy.  J Clin Invest. 2003;  111 419-426
    PubMedGoogle Scholar
  • 73 Young ME, MacNulty P, Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes: Part II: potential mechanisms.  Circulation. 2002;  105 1861-1870
    CrossrefPubMedGoogle Scholar
  • 74 Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta.  Science. 2001;  293 1673-1677
    CrossrefPubMedGoogle Scholar
  • 75 Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, Orci L, Unger RH. Lipotoxic heart disease in obese rats: implications for human obesity.  Proc Natl Acad Sci USA. 2000;  97 1784-1789
    CrossrefPubMedGoogle Scholar

Correspondence

Univ. Prof. Dr. Dr. D. Tschoepe

Heart and Diabetes Center NRW

Ruhr-University Bochum

Georgstraße 11

32545 Bad Oeynhausen

Germany

Phone: +49/5731/97 22 92

Fax: +49/5731/97 19 67

Email: dtschoepe@hdz-nrw.de

      >